BOSTON and SOUTH SAN FRANCISCO, Calif. -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced upcoming presentations featuring preclinical data on its novel dual KRASG12C inhibitor FMC-376 and advances from the Frontier™ Platform. These data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place April 14th-19th in Orlando, Florida.
Preclinical data unveiling FMC-376’s discovery and unique mode of action will be featured in an oral mini-symposium on Small Molecule Therapeutic Agents on April 16th, followed by a presentation on the FrontierPlatform in an April 18th poster session.
“Decades after the human genome project, there remains a high unmet need for effective and durable breakthrough precision medicines targeting previously undruggable targets like KRAS,” said Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO. “We are excited to share data showing how our novel dual inhibitor FMC-376 is designed to rapidly and directly shut down both active and inactive KRASG12C. These findings further validate the ability of the Frontier Platform to unlock the proteome for the discovery of treatments that can potentially create a better future for people with cancer and other serious conditions.”
Details on the presentations are as follows:
Title: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C
Abstract Number: 1142
Oral Session Title: Small Molecule Therapeutic Agents
Session Date and Time: Sunday, April 16, 2023, 3-5 p.m. ET
Title: Combining chemoproteomics with machine learning identifies functionally active covalent fragments for hard-to-drug cancer drivers
Abstract Number: 5333
Oral Session Title: High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery
Session Date and Time: Tuesday, April 18, 2023, 1:30-5 p.m. ET
About Frontier Medicines
Frontier Medicines is a precision medicine company that has pioneered a powerful drug discovery engine, the Frontier™ Platform, designed to generate medicines against disease-causing proteins previously considered undruggable. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to develop potentially groundbreaking medicines for genetically-defined patient populations, starting in cancer. Frontier is advancing a deep pipeline of wholly-owned precision medicines against the most important drivers of cancer. The company’s lead candidate, FMC-376, is a dual inhibitor of active and inactive KRASG12C. By completely blocking both forms of the KRAS mutation, FMC-376 has the potential to overcome the non-response and resistance seen with single-acting KRASG12C inhibitors. For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter.